JASON SEED: Open Payments
NPI 1316312267 · ROGERS, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,232 in 98 payments from 12 companies in 2025. Trend: 2023 $333 · 2024 $1,645 · 2025 $2,232
Food & beverage: $2,131Education: $101
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 13 | $535 |
| Alkermes, Inc. | 19 | $400 |
| Teva Pharmaceuticals USA, Inc. | 15 | $347 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $234 |
| Janssen Pharmaceuticals, Inc | 7 | $193 |
| ABBVIE INC. | 11 | $181 |
| Otsuka America Pharmaceutical, Inc. | 4 | $97 |
| E.R. Squibb & Sons, L.L.C. | 5 | $94 |
| Axsome Therapeutics, Inc. | 2 | $50 |
| Lundbeck LLC | 2 | $42 |
Products named: ARISTADA, HETLIOZ, FANAPT, CAPLYTA, VRAYLAR, INVEGA SUSTENNA, AUSTEDO XR, REXULTI.
Industry payments across AR — which companies pay providers there.
